AGIO Dec 2024 35.000 put
| Previous Close | 7.20 |
| Open | 7.30 |
| Bid | 5.80 |
| Ask | 7.50 |
| Strike | 35.00 |
| Expire Date | 2024-12-20 |
| Day's Range | 7.10 - 7.30 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 548 |
Simply Wall St.Swelling losses haven't held back gains for Agios Pharmaceuticals (NASDAQ:AGIO) shareholders since they're up 71% over 1 year
Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than...
GlobeNewswireAgios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with Mitapivat Compared to Placebo – – Agios to Webcast Virtual Investor Event on June 16, 2024 at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time – CAMBRIDGE, Mass., June 15, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasd
ZacksPrestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?
Prestige Consumer Healthcare (PBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
